Common Stock, $0.01 par value
- Symbol
- VRDN
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Viridian Therapeutics, Inc.
VRDNNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On August 6, 2026, Viridian Therapeutics, Inc. issued a press release reporting financial results for the quarter ended June 30, 2026.…
Press release in this filing
Viridian Therapeutics Highlights Recent Business Progress and Reports Second →Company context
Viridian Therapeutics is a biotechnology company dedicated to developing better medicines for patients with autoimmune and rare diseases. Utilizing our expertise in antibody discovery and protein engineering, we aim to build on proven science to develop innovative medicines that address unmet needs and improve patient outcomes. With an immediate focus in thyroid eye disease (TED), we developed Lumvoa, a full IGF-1R antagonist approved by the U.S. FDA for the treatment of thyroid eye disease. We are also advancing elegrobart, a late-stage investigational subcutaneous therapy designed to further address unmet needs in TED and improve patient convenience. Beyond TED, we are advancing a pipeline of potential best-in-class medicines to address multiple serious autoimmune diseases.
Current securities
Recent company filings
- SCHEDULE 13G - filed by Point72 Asset Management, L.P. regarding Viridian Therapeutics, Inc.\DEAug 20, 2026
- 144 filingAug 19, 2026
- SCHEDULE 13G/A - filed by Kynam Capital Management, LP regarding Viridian Therapeutics, Inc.\DEAug 14, 2026
- SCHEDULE 13G/A - filed by Deep Track Capital, LP regarding Viridian Therapeutics, Inc.\DEAug 14, 2026
- 10-Q filingAug 6, 2026
Registered securities in this filing
Viridian Therapeutics, Inc.\DE · 8-K · Filed 2026-08-06
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition
On August 6, 2026, Viridian Therapeutics, Inc. issued a press release reporting financial results for the quarter ended June 30, 2026.
The press release is attached hereto as Exhibit 99.1, which is furnished under Item 2.02 of this Current Report on Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.
Filed exhibits (1)
EX-99.1 2 d174744dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results - Lumvoa ™ (veligrotug-vvze) approved by the FDA for thyroid eye disease (TED) on June 26, 2026, ahead of target PDUFA date and immediately launched in the U.S. - - Elegrobart, potentially the first subcutaneous autoinjector for the treatment of TED, on track for BLA submission Q1 2027 - - Pipeline progress continues, with FcRn and TSHR program development milestones on track in 2026 - - Completed convertible debt and equity financing in May 2026 with gross proceeds of $394 million; cash, cash equivalents, and marketable securities of $982 million as of June 30, 2026 - WALTHAM, Mass. - August 6, 2026 - Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported recent business highlights and financial results for the second quarter ended June 30, 2026. “We are very encouraged by the early indications from our recent launch of Lumvoa as we start a new chapter…
Open exhibit ↗